Ways to fit a PK model with some data below the quantification limit, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.481-504, 2001. ,
DOI : 10.1023/A:1012299115260
NONMEM User's Guide; NONMEM project group, 1998. ,
Mirochnick, and a. f. t. P. I. P. s. Team, Presented at the 15th Conference on Retroviruses and Opportunistic Infections, pp.3-6, 2008. ,
Steady-State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.39, issue.6, pp.751-760, 2007. ,
DOI : 10.1177/0091270007300951
R: a language for data analysis and graphics, J Comput Graph Stat, vol.5, p.299, 1996. ,
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission, AIDS, vol.14, pp.111-116, 2000. ,
Drug disposition and pharmacokinetics in the maternal-placental-fetal unit, Pharmacology & Therapeutics, vol.10, issue.2, pp.301-329, 1980. ,
DOI : 10.1016/0163-7258(80)90085-6
Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, vol.865, pp.81-90, 2008. ,
Pharmacokinetic Changes During Pregnancy and Their Clinical Relevance, Clinical Pharmacokinetics, vol.33, issue.5, pp.328-371, 1997. ,
DOI : 10.2165/00003088-199733050-00002
Antiretroviral Pharmacology in Pregnant Women and Their Newborns, Annals of the New York Academy of Sciences, vol.42, issue.1, pp.287-97, 2000. ,
DOI : 10.1111/j.1749-6632.2000.tb05498.x
TRANSIT TIME IN THE SMALL INTESTINE IN PREGNANCY, BJOG: An International Journal of Obstetrics and Gynaecology, vol.77, issue.10, pp.900-901, 1970. ,
DOI : 10.1111/j.1471-0528.1970.tb03423.x
Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.PAP, pp.274-283, 2007. ,
DOI : 10.1097/QAI.0b013e318050d88c
Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1- infected women and newborn infants, J Infect Dis, vol.180, pp.1844-50, 1999. ,
Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children, Antimicrob Agents Chemother, vol.48, pp.183-91, 2004. ,
Pharmacokinetic Evaluation of Emtricitabine in Combination With Other Nucleoside Antivirals in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.191, issue.suppl 2A, pp.877-89, 2007. ,
DOI : 10.1177/0091270007300808